Pediatrix Medical Group has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.3%. The stock now trades at $25.83, marking a 19.9% gain. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Is there a buying opportunity in Pediatrix Medical Group, or does it present a risk to your portfolio? Get the full breakdown from our expert analysts, it’s free.

Why Is Pediatrix Medical Group Not Exciting?

We’re happy investors have made money, but we don’t have much confidence in Pediatrix Medical Group. Here are three reasons why MD doesn’t excite us, plus one stock we’d rather own.

1. Long-Term Revenue Growth Disappoints

A company’s long-term sales performance is one signal of its overall quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. Regrettably, Pediatrix Medical Group’s sales grew at a tepid 2.1% compounded annual growth rate over the last five years. This fell short of our benchmarks.

2. Projected Revenue Growth Shows Limited Upside

Forecasted revenues by Wall Street analysts signal a company’s potential. Predictions may not always be accurate, but accelerating growth typically boosts valuation multiples and stock prices while slowing growth does the opposite.

Over the next 12 months, sell-side analysts expect Pediatrix Medical Group’s revenue to stall. While this projection suggests its newer products and services will fuel better top-line performance, it is still below the sector average.

3. New Investments Fail to Bear Fruit as ROIC Declines

ROIC, or return on invested capital, is a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity).

Unfortunately, Pediatrix Medical Group’s ROIC has decreased over the last few years. Paired with its already low returns, these declines suggest its profitable growth opportunities are few and far between.

Final Judgment

Pediatrix Medical Group isn’t a terrible business, but it doesn’t pass our quality test. With its shares beating the market recently, the stock trades at 11.5× forward P/E (or $25.83 per share). This valuation multiple is fair, but we don’t have much faith in the company. We’re fairly confident there are better investments elsewhere. Let us point you toward the Amazon and PayPal of Latin America.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.